Where AI is actually being used in Gulf healthcare

Beyond the AI-in-healthcare headline It is worth being specific about what counts as evidence here. A broad announcement of an "AI strategy" is not the same as a funded company with a specific product deployed against a specific clinical or operational problem. This piece deliberately restricts itself to the latter — companies with disclosed funding, a named product category, and in most cases a specific market or expansion target — because that is the level of detail that actually distinguishes a real deployment from an aspiration. "AI is transforming healthcare" is one of the most repeated and least specific claims in technology coverage anywhere in the world. In the Gulf, though, a handful of funded companies are working across genuinely different parts of the healthcare system — virtual care, diagnostics infrastructure and longevity research. Looking at what these companies actually do is more useful than the general claim. Virtual care and mobile diagnostics: Waspito Starting with Waspito makes sense given the size of the recognition it has already received, but its relevance to Gulf healthcare specifically comes less from the award and more from the stated intent to bring its model into the Saudi market next. Waspito , the telemedicine platform that became the first African startup to win LEAP's $250,000 grand prize, built its business around connecting patients to doctors remotely and operating mobile labs that bring diagnostic testing to patients who cannot easily reach a clinic. That combination — virtual consultations paired with mobile, physical lab infrastructure — addresses the problem of patients who cannot easily reach a clinic or a lab. Waspito's plans following its LEAP win include exploring the Saudi market directly. Mobile diagnostic infrastructure of the kind Waspito operates is also, implicitly, a data-generation exercise: every mobile lab visit produces structured diagnostic data that, over time, can feed the same kind of AI-assisted triage and risk-scoring tools that more established health systems are starting to use. Targeting the Saudi market directly: CareVision CareVision , which won LEAP's $150,000 Landing Award, is targeting entry into the Saudi market. Details of the company's product beyond the award and its Saudi entry plans are limited in the material TechScoop reviewed, so this piece does not characterise its care model or its use of AI. A company entering an established Gulf healthcare market rather than building one from scratch typically needs to compete on integration with existing hospital and insurance systems as much as on the underlying technology itself, which makes CareVision's stated Saudi entry plans as significant a detail as its award. Patient engagement: the layer with the least public detail Patient engagement — the tools that keep patients following treatment plans, attending follow-up appointments and staying in contact with providers between visits — is the one theme in this space with the least specific, disclosed detail among the companies covered here. That gap is worth naming rather than glossing over: much of the public conversation about AI in healthcare, in the Gulf and elsewhere, focuses on this layer because it is the most consumer-visible, yet the companies with the clearest disclosed funding and product detail in this piece are concentrated instead in diagnostics, virtual consultations and longevity research. That suggests patient engagement AI in Gulf healthcare may be earlier-stage or less publicly documented than the more clinical layers covered above, rather than genuinely less active. Longevity and diagnostics research: Longevium Longevity is the newest and least conventional category covered in this piece, and it is worth including precisely because it shows Gulf-region healthtech investment is not confined to the more familiar categories of virtual care and diagnostics alone. At the more specialized end of the spectrum, Longevium raised $7 million to build an AI-powered longevity research lab based at Dubai Science Park. Longevity research sits at the intersection of diagnostics and prevention: rather than treating disease after it appears, the field is built around using data — increasingly AI-analyzed biomarker and diagnostic data — to identify risk earlier and intervene sooner. A dedicated, AI-driven longevity lab is a different model from a hospital or clinic network. What the pattern shows None of these three companies compete directly with each other — telemedicine and mobile labs, a Saudi market-entry play, and longevity research are different businesses solving different problems. What connects them is that each is building a technology-enabled model at the edges of traditional care delivery. Longevium is the one whose AI use is explicit in its disclosures — its lab is described as AI-powered. Waspito's mobile labs generate diagnostic data that AI tools could in time help interpret, and CareVision has not yet detailed its produc